📋 Tender Overview
The subject of this publication is the conclusion of non-exclusive discount agreements for medicines containing the active ingredient Certolizumab pegol. The contract is concluded within the framework of an Open-House model, meaning that a contract conclusion is open to all interested pharmaceutical companies during the participation period, provided they meet and accept the participation requirements. Individual contract negotiations will not be conducted and exclusivity is not given. The purchase quantity is unknown and depends on demand and various factors. Minimum purchase quantities are not guaranteed. Certolizumab pegol
